Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Rat dog micro-cap picks... -- Ignore unavailable to you. Want to Upgrade?

To: CusterInvestor who wrote (12061)	5/21/2003 4:43:16 PM
From: BW	Read Replies (1) \| Respond to of 48461

CTE - ya it looks real good, nice news today. and William always says once these amex stocks start up they tend to go for a while. do you have a sell target? 2.50 looks to pose some resistence. CardioTech Opens Lucrative Japanese Market Wednesday May 21, 9:01 am ET WOBURN, Mass., May 21 /PRNewswire-FirstCall/-- CardioTech International, Inc. (Amex: CTE - News) today announced that its wholly- owned subsidiary, Gish Biomedical, Inc. ("Gish"), has completed contract negotiations with Heiwa Bussan Co., Ltd. to distribute its heart-lung products in Japan. Approximately 27,000 cardiac surgery procedures are conducted annually in Japan and represent an important export market for Gish. Gish Biomedical is a leading manufacturer of products for the heart-lung bypass market. The Japanese medical device market is among the world's most lucrative, while requiring the most stringent quality standards. Gish Biomedical began shipping products to Heiwa Bussan in November 2002 to establish an appropriate inventory level of ready-to-ship components in Japan. Douglas E. Whittaker, President of Gish, stated: "We are extremely pleased to have reached this agreement with Heiwa Bussan to distribute our products in Japan. We worked closely with them to gain approval from Japan's Ministry of Health, Japan's equivalent to the American FDA. I expect this agreement to add significantly to our revenues." Dr. Michael Szycher, CEO of CardioTech, stated, "This contract not only opens doors for our current products but we also expect it to open the Japanese market for future products. The Japanese market for heart-lung products is among the most lucrative in the world." The principle of the heart-lung machine (also known as cardiopulmonary bypass) is a marvel of modern technology. Venous blood withdrawn from the patient is drained into a reservoir. From there the blood is pumped through an oxygenator. Oxygen gas is delivered to the interface between the blood and the device, permitting the blood cells to absorb oxygen molecules directly. Now the blood is red in color, indicating its rich content of oxygen. Finally, the heart-lung machine pumps the oxygenated blood back into the patient through a tube connected to the arterial circulation. The heart-lung circuit is a continuous loop. As the oxygenated blood is pumped to the body, venous blood returns from the body and is drained into the pump completing the circuit biz.yahoo.com